Cellectis therapeutics hires Dr Andrew Scharenberg as CSO
This article was originally published in Scrip
Cellectis therapeutics has appointed Dr Andrew Scharenberg chief scientific officer. Dr Scharenberg is an attending physician in immunology at Seattle Children's Hospital, a principal investigator and co-director of the Northwest Genome Engineering Consortium, and co-founder and a member of the board of directors of Pregenen, a biotechnology spin-off from the NGEC and a strategic partner of Cellectis.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.